About Daewoong
Affiliates
Holding Company
-
- Daewoong
- Resource management and management support for affiliated companies
- Go to homepage
Daewoong Affiliates
-
- Daewoong Pharmaceutical
- Manufacture and sales of finished dose
- Go to homepage
-
- Daewoong Bio
- Manufacture and sales of API
- Go to homepage
-
- Daewoong Life Science
- Production and sales of health food and life products
- Go to homepage
-
- DMD Daewoong Management Development Institute
- Corporate personnel training business
- Go to homepage
-
- idsTrust
- Computer, peripheral devices and software development and sales
- Go to homepage
-
- Daewoong ENG
- Facility management services and machine production
- Go to homepage
-
- Daewoong Development
- Real estate leasing
-
- Daewoong Therapeutics
- R&D on first-in-class DR/DDS-based new drugs
- Go to homepage
-
- Daewoong pet
- Manufacture and sales of veterinary medicine
- Go to homepage
Daewoong Pharmaceutical Affiliates
-
- Hanall Biopharma
- Pharmaceutical product R&D
- Go to homepage
-
- MD Well
- Medicine and nutrition company, production and sales of nutritious meals
- Go to homepage
-
- Seonmaeul
- New conceptual lifestyle improvement program, and the nation’s first wellness center
- Go to homepage
-
- Affyxell Therapeutics
- R&D on pharmaceutical drugs and medicine
- Go to homepage
-
- iN Therapeutics
- R&D on pharmaceutical drugs and medicine
- Go to homepage
-
- DaNaA Data
- Big Data / AI-based healthcare business
- Affyxell Therapeutics
- R&D on pharmaceutical drugs and medicine
Seng Ho Jeon & Jong Sang Ryu
February 06, 2020
Kimhae, Korea
(Kimhae Biomedical Center)
Yong In, Korea (Gwanggyo)
healthy, joyful, and gratifying,
free from suffering of illnesses.
affordable cellular therapeutics that
help patients recover from intractable
disease and regain their health.
Limit 1.
Limitations of Current Stem
Cell Therapy
-
Donor variance
-
High cost
Low efficacy -
Need for
specific MoA
Limit 2.
Limitations of Current Non-IgG
Scaffold
-
Relatively short
Half-life compared to
Antibody drugs -
Low efficacy
Compared to
Competitive
treatments -
Lack of feasible
New substances
Overcoming Barriers
Next Generation Cell Therapy
(AFX Platform)
AFX platform :
Affimer-encoded Mesenchymal Stem Cells
① Overcoming donor variance by using
pluripotent stem cell-derived MSC
② Improved productivity
in cell therapy by using pluripotent
stem cell-derived MSC
③ Securing specific treatment
mechanism through Affimer gene
introduction
④ Synergy through
platform convergence
In-body factory :
overcoming a short half-life of
Affimer Superior efficacy expected
compared to
competitor treatments
* Pluripotent stem cell-derived Mesenchymal Stem Cell